| 10674ETCTN |
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination
with ASTX727 in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia
(AML) |
Open |
| 1718GCCC-S17 |
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and
venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients
>/= 60 years with NPM1 mutated AML or Mixed Lineage Leukemia (MLL) Gene Rearrangements |
Open |
| 1718GCCC-S21 |
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial
to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy
of ZE46-0134 in Adults with FLT3 mutated or Spliceosome mutated Relapsed or Refractory
Acute Myeloid Leukemia (AML) |
Open |
| 2095GCCC |
A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients
with Relapsed or Refractory Acute Myeloid Leukemia |
Open |
| 2254GCCC |
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific
DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies |
Open |
| 2282GCCC |
A prospective randomized, double-blind, placebo-controlled, multi-center phase III
study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance
treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic
cell transplantation (HCT) |
Open |
| 24101GCCC |
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult
Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and
without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation |
Open |
| 24105GCCC |
Registry and Biobank of Patients with a History of Cancer Therapy |
Open |
| 2458GCCC |
Take the Reins: The effects of nutrient timing on cancer-related fatigue among blood
cancer survivors |
Open |
| AAML1831 |
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy
Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3
Inhibitor Gilteritinib for Patients with FLT3 Mutations
|
Open |